Cite
HARVARD Citation
Williams, K. et al. (2020). Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years. Journal of infectious diseases. pp. 979-988. [Online].